Literature DB >> 9562283

Severe sepsis in cardiac surgical patients.

A Michalopoulos1, G Stavridis, S Geroulanos.   

Abstract

OBJECTIVE: To elucidate the incidence, determinants, and consequences of severe sepsis after cardiac surgery.
DESIGN: Prospective study.
SETTING: Cardiac surgical unit, Greece.
SUBJECTS: 2615 adult patients having cardiac operations. MAIN OUTCOME MEASURES: Microbiological evidence of sepsis, mortality, and duration of stay in the intensive care unit (ICU) and hospital.
RESULTS: Severe sepsis developed in 41/2615 patients (2%), all during their stay in the ICU: there were 30 men and 11 women, mean (SD) age 65 (10) years. It was most common after combined coronary artery bypass grafting and valve-related operations (7/95, 7%), followed by miscellaneous cardiac operations (7/147, 5%), valve replacement (8/359, 2%), and coronary artery bypass grafting (19/2014, 1%). When the 41 patients who developed severe sepsis were compared with those who did not (n = 2574) by univariate analysis, there were significant differences in age (p = 0.004); type of operation (p < 0.0001); duration of operation (p < 0.001); bleeding that necessitating either reoperation or significantly more blood transfused (p < 0.0001); and the incidence of low cardiac output syndrome (p = 0.0001). Of the 41 patients with severe sepsis, 19 (46%) had serious operative complications, 40 (98%) had severe complications in the ICU, and 16 (39%) required reintubation for hypoxaemia. Among the 41 there were 54 bacteraemic episodes of which 37 (69%) were caused by gram positive cocci, 6 (11%) by gram negative bacteria, and 11 (20%) by Candida albicans. Staphylococcus epidermidis was the most common pathogen isolated (n = 26, 48%). Sepsis associated with bacterial infection usually developed during the first two weeks, and that caused by fungal infection was most common after the twentieth postoperative day. Patients with severe sepsis required longer mechanical ventilation (31 (21) days compared with 0.9 (0.1) days); longer stay in the ICU (40 (25) days) compared with 2 (1) days); longer stay in hospital (48 (27) days compared with 10 (2) days); and significantly more of them died (13 (32%) compared with 41 (2%), p < 0.0001 in each case).
CONCLUSIONS: We concluded that severe sepsis mainly developed in cardiac surgery patients with serious operative and postoperative complications and was associated with a longer stay in both ICU and hospital, and a higher mortality.

Entities:  

Mesh:

Year:  1998        PMID: 9562283     DOI: 10.1080/110241598750004670

Source DB:  PubMed          Journal:  Eur J Surg        ISSN: 1102-4151


  12 in total

1.  Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: results of a prospective, randomized, controlled clinical trial.

Authors:  Jill M Cholette; Kelly F Henrichs; George M Alfieris; Karen S Powers; Richard Phipps; Sherry L Spinelli; Michael Swartz; Francisco Gensini; L Eugene Daugherty; Emily Nazarian; Jeffrey S Rubenstein; Dawn Sweeney; Michael Eaton; Norma B Lerner; Neil Blumberg
Journal:  Pediatr Crit Care Med       Date:  2012-05       Impact factor: 3.624

2.  Risk factors for sepsis and endocarditis and long-term survival following coronary artery bypass grafting.

Authors:  Ioannis K Toumpoulis; Constantine E Anagnostopoulos; Stavros K Toumpoulis; Joseph J De Rose; Daniel G Swistel
Journal:  World J Surg       Date:  2005-05       Impact factor: 3.352

3.  Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.

Authors:  Christian Radke; Dagmar Horn; Christian Lanckohr; Björn Ellger; Michaela Meyer; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

4.  Transfusion in Elective Proximal Aortic Reconstruction: Where Do We Currently Stand?

Authors:  Stevan S Pupovac; Jonathan M Hemli; S Jacob Scheinerman; Alan R Hartman; Derek R Brinster
Journal:  Int J Angiol       Date:  2021-07-30

5.  Susceptibility to thrombin-induced platelet microbicidal protein is associated with increased fluconazole efficacy against experimental endocarditis due to Candida albicans.

Authors:  Michael R Yeaman; Darwin Cheng; Bhavesh Desai; Leon I Kupferwasser; Yan-Qiong Xiong; Kimberly D Gank; John E Edwards; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

6.  Transfusion and bleeding in coronary artery bypass grafting: an on-pump versus off-pump comparison.

Authors:  Kieron C Potger; Darryl McMillan; Joanne Southwell; Terry Connolly; Kate Kingsford Smith; Mark Ambrose
Journal:  J Extra Corpor Technol       Date:  2007-03

7.  Incidence and outcomes of sepsis after cardiac surgery as defined by the Sepsis-3 guidelines.

Authors:  S H Howitt; M Herring; I Malagon; C N McCollum; S W Grant
Journal:  Br J Anaesth       Date:  2017-11-24       Impact factor: 9.166

8.  Prospective comparison of eubacterial PCR and measurement of procalcitonin levels with blood culture for diagnosing septicemia in intensive care unit patients.

Authors:  Farjana B Rowther; Camilla S Rodrigues; Minal S Deshmukh; Farhad N Kapadia; Ashit Hegde; Ajita P Mehta; Vinay R Joshi
Journal:  J Clin Microbiol       Date:  2009-07-29       Impact factor: 5.948

9.  A comparative study of four intensive care outcome prediction models in cardiac surgery patients.

Authors:  Fabian Doerr; Akmal Ma Badreldin; Matthias B Heldwein; Torsten Bossert; Markus Richter; Thomas Lehmann; Ole Bayer; Khosro Hekmat
Journal:  J Cardiothorac Surg       Date:  2011-03-01       Impact factor: 1.637

10.  A multi-centre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, morbidity and healthcare resource use following cardiac surgery: study protocol.

Authors:  Rachel C M Brierley; Katie Pike; Alice Miles; Sarah Wordsworth; Elizabeth A Stokes; Andrew D Mumford; Alan Cohen; Gianni D Angelini; Gavin J Murphy; Chris A Rogers; Barnaby C Reeves
Journal:  Transfus Apher Sci       Date:  2014-03-12       Impact factor: 1.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.